News – Page 1167 – Endpoints News

GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

9 years ago

Sarepta rockets up after FDA approves its controversial Duchenne drug

9 years ago

Scoop: J&J confirms that the FDA put AML drug on complete hold

9 years ago

Benitec’s abandoned one-dose hep C “cure” actually had two big problems

9 years ago

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

9 years ago

Amgen’s expectations for romosozumab take a hit as Radius lines up its rival osteoporosis drug

9 years ago

Novartis shows a hole card in a high-stakes PhIII poker game for MS drugs

9 years ago

Amgen partners with Genenta, San Raffaele on an anti-tumor drug

9 years ago

Thumbs Up/Thumbs Down: The UN fumbles badly over access to drugs while developers think again about R&D strategies

9 years ago

Novo’s big reveal: GLP-1 drug semaglutide cuts cardio risks, but just may blind you

9 years ago

An acquisitive Celgene looks ready to pop a new multiple myeloma deal

9 years ago

Amgen, Novartis celebrate promising migraine data, but Teva and Alder are preparing to crash the party

9 years ago

The gamma delta T cell gambit inspires a small London biotech startup with big ideas

9 years ago

Novavax shares are routed after its big PhIII RSV vaccine trial flops

9 years ago

IPO-bound Intarcia hauls in $215M, and plans to add more; Peloton raises $52M round

9 years ago

Aralez finally gets an FDA OK for its cardio drug Yosprala, starts hiring sales reps

9 years ago

Merck, Pfizer tout PhIII diabetes data as ertuglifozin heads to the FDA

9 years ago

Rigel co-founder, R&D staff jettisoned in the long-awaited lead up to an FDA pitch

9 years ago

Eisai launches biotech division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases

9 years ago

AcelRx takes another step in its recovery program, prepping a pain med pitch to the FDA

9 years ago

Aerie shares rocket up as glaucoma combo drug scores positive data

9 years ago

Agios sets out to raise $150M; AC Immune IPO sets valuation at $700M

9 years ago

The FDA confirms that Sarepta nemesis Ronald Farkas has left the agency

9 years ago

Roche’s megablockbuster MS candidate ocrelizumab posts promising head-to-head data

9 years ago

First page Previous page 1164 1165 116611671168 1169 1170 Next page Last page